Generic Name and Formulations:
Dexrazoxane 500mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.
Cumberland Pharmaceuticals, Inc.
Indications for TOTECT:
To treat extravasation resulting from IV anthracycline chemotherapy.
Give once daily for 3 consecutive days by IV infusion over 1–2 hours. Initiate 1st dose as soon as possible and within 1st 6 hours after extravasation. Days 1 and 2: 1000mg/m2; max 2000mg. Day 3: 500mg/m2; max 1000mg. Renal impairment (CrCl <40mL/min): reduce dose by 50%.
Renal or hepatic impairment (monitor). Monitor for myelosuppression; obtain blood counts periodically. Elderly. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.
Avoid dimethylsulfoxide (DMSO). Caution with concurrent cytotoxic chemotherapy (additive cytotoxicity).
Inj site reactions, nausea, vomiting, pyrexia, infections, leukopenia, neutropenia, thrombocytopenia, elevated liver enzymes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Nicotinamide and Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML